Please login to the form below

Not currently logged in
Email:
Password:

Reata

This page shows the latest Reata news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Daily Brief: EU agencies brace for No Deal Brexit, GSK mulls spin-off, Realta scores in CKD

Reata Pharma success in kidney disease treatment. Reata Pharmaceuticals has produced phase II results showing its bardoxolone methyl (bardoxolone) can prevent or dealy kidney failure in a rare form of chronic ... Reata collected historical eGFR data for

Latest news

  • Abbott agrees $400m chronic disease deal with Reata

    The pharma company will make a one-off payment of $400m to Texas, US-based Reata Pharmaceuticals for its second-generation oral antioxidant inflammation modulators (AIMs). ... For these conditions, Abbott will take 70 per cent of costs and profits, while

  • Regional plans

    A similar rationale applies to the deal between Abbott and Reata where Abbott will be providing the global marketing capability outside the US. ... Platform. 480. PregLem/Richter. Corporate acquisition.  . 461. Reata/Abbott. Bardoxolone for chronic

  • Abbott signs kidney drug deal

    Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney disease. ... Abbott has licensed rights from Reata Pharmaceuticals to develop and commercialise a phase II drug for chronic kidney

  • Advancing acquisitions

    P1 . 334. Reata Pharma/Kyowa Hakko . Bardoxolone in chronic kidney disease. P2a .

More from news
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics